1 / 11

KEMRI-Wellcome Trust Research Programme

joyceta
Download Presentation

KEMRI-Wellcome Trust Research Programme

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. The Impact of Retail Sector Delivery of Artemether-Lumefantrine on Effective Malaria Treatment of Children Under Five in KenyaSarah V. Kedenge Beth Kangwana; Abdisalan M. Noor; Victor A. Alegana ; Andrew J Nyandigisi ; Jayesh Pandit ; Greg W Fegan ; Simon Brooker; Robert W Snow; Catherine A. Goodman KEMRI-Wellcome Trust Research Programme

  2. General Study Design • Design: pre-post randomized cluster controlled trial to compare intervention and control areas Teso Busia Butere Mumias

  3. Survey Activities Household and retail censuses, household, provider and mystery shopper surveys and FGDs

  4. Description of Under 5 Population Surveyed • 3,288 households surveyed at baseline and 3,182 at follow up • Total Under 5 population surveyed was 2,749 and 2,662 at baseline and follow up respectively • Fever prevalence in children 3-59 months (in past 2 weeks) averaged at 28% at baseline and 30% at follow up Fever treatment actions taken by caregivers • 86% of fevers experienced within 2 weeks of the interview had some action taken by caregiver • Majority of actions were visits made to government facilities (31%) and specialized drug stores (33%) • Also frequently used were general stores (18%)

  5. Anti-malarials Received RECEIVED AN ANTI MALARIAL RECEIVED AN ANTI- MALARIAL MONOTHERAPY

  6. Children 3-59 months who received AL on the same day or following day of fever developing

  7. Adherence ADHERED TO THE RIGHT DOSE ADHERED TO THE RIGHT PRICE • 95% of those purchasing Tibamal reported paying the recommended retail price of 20KSH ($0.25)

  8. Study Limitations • Distribution of AL • Study limited to children 3-59 months • Studies limited to one province which is malaria endemic and at the Kenyan-Ugandan border • Difficult to determine future changes in treatment seeking behavior

  9. Policy Implications & Lessons learnt • Subsidizing ACTs in the retail sector can lead to a substantial increase in coverage in prompt and effective treatment • Although the design of the intervention differs with that of AMF-m, the findings can be cautiously interpreted to demonstrate how crowding out anti-malarial monotherapies and increasing access to AL by increasing its distribution at decreased costs could work • Further research required to: - assess feasibility of introducing diagnosis at retail outlets to improve targeting of ACT. - come up with innovative and practical strategies to improve drug adherence both in the public and private sector.

  10. Acknowledgements • Division of Malaria Control: Dr Juma, Dr Akhwale, Dr Memusi, Dr Nyandigisi and the team • Pharmacy and Poisons Board: Dr Pandit • Population Services International : Manya Andrews and Mbogo Bunyi and the rest of the team • DFID, USAID and the Wellcome Trust • DHMTs and DOs in Teso, Butere Mumias and Busia • Field workers, shopkeepers and care givers

More Related